Truist Securities Adjusts Price Target on Hims & Hers Health to $23 From $13, Maintains Hold Rating
Hims & Hers Health Analyst Ratings
Piper Sandler Adjusts Price Target on Hims & Hers Health to $18 From $16, Maintains Neutral Rating
Hims & Hers Health Analyst Ratings
Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and Gain Therapeutics (GANX)
Buy Rating Affirmed for Hims & Hers Health on Strong GLP-1 Product Launch and Revenue Growth
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Hims & Hers Health's Strategic Growth in Weight Loss Market Warrants Buy Rating Despite Regulatory Risks
Deutsche Bank Adjusts Hims & Hers Health Price Target to $16 From $14, Maintains Hold Rating
Buy Rating Affirmed for Hims & Hers Health Amidst Strong Quarterly Performance and Positive Outlook
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Hims & Hers Health Outperforms: Strong Sales Growth and Brand Value Reinforce Buy Rating
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Hims & Hers Health (HIMS) and Olink Holding (OLK)